Mumps virus transmission in vaccinated populations, WP 2: short-term and long-term complications of mumps-associated orchitis in vaccinated men * a prospective multicenter cohort trial

Published: 03-11-2011 Last updated: 29-04-2024

To assess short-term and long-term complications of mumps-associated orchitis in vaccinated

men

Ethical reviewApproved WMOStatusRecruitment stoppedHealth condition typeViral infectious disordersStudy typeObservational invasive

Summary

ID

NL-OMON36170

Source

ToetsingOnline

Brief title

Complications of mumps-associated orchitis in vaccinated men

Condition

- Viral infectious disorders
- Male reproductive tract infections and inflammations

Synonym

mumps, orchitis

Research involving

Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum

Source(s) of monetary or material Support: ZonMw

Intervention

Keyword: cryopreservation, mumps, orchitis, semen quality

Outcome measures

Primary outcome

Semen quality during initial non-infective phase of mumps orchitis and

follow-up during at least 6 months period which can be lengthened if indicated.

Secondary outcome

Levels of FSH, LH, testosterone, SHBG and Inhibin B during the abovementioned 6 month period.

If possible hormone levels and semen quality after one year.

Study description

Background summary

Despite a successful vaccination programme over many years, mumps has re-emerged. So far, outbreaks in fully vaccinated populations have been concentrated among young adults with close social interactions. In the Netherlands, an outbreak is ongoing since late 2009 among university students in various towns.

Therefore, the RIVM/CIb convened an Outbreak Management Team (OMT) on January 31st 2011 to discuss the situation, to assess additional control options, and to identify unresolved research questions. A major question is to improve understanding of the long-term clinical outcome of mumps-associated orchitis in vaccinated men with respect to their fertility.

Study objective

To assess short-term and long-term complications of mumps-associated orchitis

in vaccinated men

Study design

Observational study

Study burden and risks

Participating in this study does not cause any risks for the subjects. The burden solely consists of the visits to the clinic and venapunctions.

Contacts

Public

Academisch Medisch Centrum

Meibergdreef 9 1105 AZ Amsterdam NL

Scientific

Academisch Medisch Centrum

Meibergdreef 9 1105 AZ Amsterdam NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

All men of 18 or more prospectively diagnosed with acute uni- or bilateral mumps-associated orchitis in the Netherlands after vaccination are eligible for inclusion.

Exclusion criteria

Exclusion criteria are the inability to ejaculate, the inability to provide written informed consent and risk factors in the medical history for decreased fertility (e.g. cancer, gonadal dysplasia, cryptorchidism etc).

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 09-02-2012

Enrollment: 30

Type: Actual

Ethics review

Approved WMO

Date: 03-11-2011

Application type: First submission

Review commission: METC Amsterdam UMC

Approved WMO

Date: 14-02-2012

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 23-02-2012

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 06-06-2012

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 21-06-2012

Application type: Amendment

Review commission: METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL36899.018.11